815 related articles for article (PubMed ID: 25601535)
1. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
2. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
Sophie R; Lu N; Campochiaro PA
Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
Campochiaro PA; Wykoff CC; Shapiro H; Rubio RG; Ehrlich JS
Ophthalmology; 2014 Sep; 121(9):1783-9. PubMed ID: 24768239
[TBL] [Abstract][Full Text] [Related]
8. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
9. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
[TBL] [Abstract][Full Text] [Related]
10. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema.
Srinivas S; Verma A; Nittala MG; Alagorie AR; Nassisi M; Gasperini J; Sadda SR
Am J Ophthalmol; 2020 Mar; 211():183-190. PubMed ID: 31758926
[TBL] [Abstract][Full Text] [Related]
12. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
[TBL] [Abstract][Full Text] [Related]
14. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
[TBL] [Abstract][Full Text] [Related]
15. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
Ebneter A; Wolf S; Zinkernagel MS
Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
18. Effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema.
Douvali M; Chatziralli IP; Theodossiadis PG; Chatzistefanou KI; Giannakaki E; Rouvas AA
Ophthalmologica; 2014; 232(3):136-43. PubMed ID: 25171753
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
